Clinical trial • Phase I • Endocrinology
NNC1679-0001 for Type 2 diabetes
Phase I trial of NNC1679-0001 for Type 2 diabetes. None/Not specified-controlled. 80 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 15-01-2026
- First CTIS Authorization Date
- 19-04-2026
Trial design
None/Not specified-controlled Phase I trial across 1 site in Austria.
- Comparator
- None/Not specified
- Target Sample Size
- 80
Eligibility
Recruits 80 No vulnerable populations selected; vulnerable population not included; consent/assent handling not specified..
- Vulnerable Population
- No vulnerable populations selected; vulnerable population not included; consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 80
- Recruitment Window Months
- 27
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 80
Austria
- Earliest CTIS Part Ii Submission Date
- 27-02-2026
- Latest Decision Or Authorization Date
- 19-04-2026
- Processing Time Days
- 51
- Number Of Sites
- 1
- Number Of Participants
- 80
Sites
- Site Name
- Medical University Of Graz
- Department Name
- Division of Endocrinology and Diabetology, Department of Internal Medicine
- Principal Investigator Name
- Thomas Pieber
- Principal Investigator Email
- thomas.pieber@medunigraz.at
- Contact Person Name
- Thomas Pieber
- Contact Person Email
- thomas.pieber@medunigraz.at
- Number Of Participants
- 80
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- NNC1679-0001
Related trials
Other published trials that may interest you.